Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 11 | 2019 | 666 | 1.030 |
Why?
|
| Endothelium, Vascular | 8 | 2018 | 145 | 1.020 |
Why?
|
| Brain Neoplasms | 8 | 2019 | 587 | 0.790 |
Why?
|
| Angiopoietin-1 | 4 | 2012 | 6 | 0.620 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2015 | 74 | 0.570 |
Why?
|
| Gap Junctions | 1 | 2015 | 2 | 0.540 |
Why?
|
| Connexin 43 | 1 | 2015 | 4 | 0.540 |
Why?
|
| Neovascularization, Pathologic | 5 | 2016 | 81 | 0.500 |
Why?
|
| Endothelial Cells | 1 | 2015 | 179 | 0.480 |
Why?
|
| Brain Injuries | 3 | 2018 | 94 | 0.410 |
Why?
|
| Receptor, TIE-2 | 3 | 2005 | 5 | 0.340 |
Why?
|
| Neovascularization, Physiologic | 2 | 2006 | 106 | 0.320 |
Why?
|
| Animals | 17 | 2019 | 7300 | 0.310 |
Why?
|
| Radiosurgery | 3 | 2017 | 322 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2018 | 19 | 0.310 |
Why?
|
| Cell Line, Tumor | 7 | 2019 | 681 | 0.300 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2006 | 200 | 0.300 |
Why?
|
| Cell Proliferation | 7 | 2019 | 573 | 0.300 |
Why?
|
| Radiation Injuries | 3 | 2017 | 67 | 0.290 |
Why?
|
| Gene Expression | 2 | 2018 | 332 | 0.280 |
Why?
|
| Angiopoietins | 1 | 2005 | 2 | 0.260 |
Why?
|
| Mesoderm | 1 | 2004 | 14 | 0.260 |
Why?
|
| Mice | 8 | 2019 | 2371 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2012 | 103 | 0.230 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2018 | 71 | 0.210 |
Why?
|
| Microglia | 2 | 2018 | 48 | 0.190 |
Why?
|
| Fibronectins | 2 | 2018 | 34 | 0.190 |
Why?
|
| Angiotensin I | 2 | 2013 | 262 | 0.180 |
Why?
|
| Humans | 20 | 2019 | 29123 | 0.180 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 17 | 0.170 |
Why?
|
| Cystatin A | 1 | 2019 | 8 | 0.170 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2019 | 10 | 0.170 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 29 | 0.170 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 44 | 0.170 |
Why?
|
| Peptide Fragments | 2 | 2013 | 422 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 384 | 0.160 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 33 | 0.160 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2018 | 33 | 0.160 |
Why?
|
| Receptor, erbB-2 | 2 | 2016 | 45 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 93 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 2 | 2019 | 57 | 0.160 |
Why?
|
| Exosomes | 1 | 2018 | 38 | 0.160 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 95 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2016 | 666 | 0.160 |
Why?
|
| Calcium | 1 | 2019 | 297 | 0.150 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 176 | 0.150 |
Why?
|
| Neoplasms | 1 | 2003 | 611 | 0.150 |
Why?
|
| RNA, Messenger | 3 | 2015 | 514 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 104 | 0.150 |
Why?
|
| Meningeal Neoplasms | 1 | 2017 | 46 | 0.150 |
Why?
|
| Brain | 4 | 2018 | 930 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 48 | 0.150 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 84 | 0.140 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 226 | 0.140 |
Why?
|
| Epilepsy | 1 | 2017 | 59 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2018 | 173 | 0.140 |
Why?
|
| Hippocampus | 2 | 2014 | 185 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 189 | 0.130 |
Why?
|
| Culture Media, Conditioned | 1 | 2015 | 52 | 0.130 |
Why?
|
| Cell Communication | 1 | 2015 | 30 | 0.130 |
Why?
|
| Cesium Radioisotopes | 1 | 2014 | 5 | 0.130 |
Why?
|
| Cosmic Radiation | 1 | 2014 | 13 | 0.130 |
Why?
|
| Female | 12 | 2019 | 18173 | 0.120 |
Why?
|
| Models, Biological | 3 | 2019 | 373 | 0.120 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 5 | 0.120 |
Why?
|
| Oxygen | 1 | 2014 | 139 | 0.120 |
Why?
|
| PPAR alpha | 1 | 2014 | 29 | 0.120 |
Why?
|
| Astrocytes | 1 | 2013 | 49 | 0.120 |
Why?
|
| Rats | 5 | 2014 | 1604 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2013 | 131 | 0.110 |
Why?
|
| Cognition | 2 | 2014 | 526 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 27 | 0.110 |
Why?
|
| Angiopoietin-2 | 1 | 2012 | 3 | 0.110 |
Why?
|
| Mice, Nude | 4 | 2018 | 276 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 519 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2018 | 183 | 0.100 |
Why?
|
| Phosphorylation | 3 | 2010 | 225 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2014 | 390 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 481 | 0.100 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 9 | 0.100 |
Why?
|
| Blotting, Western | 3 | 2010 | 281 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 28 | 0.090 |
Why?
|
| Survival Rate | 3 | 2019 | 795 | 0.090 |
Why?
|
| Male | 9 | 2019 | 17815 | 0.090 |
Why?
|
| Time Factors | 4 | 2013 | 2001 | 0.080 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 2 | 2006 | 2 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2109 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 342 | 0.080 |
Why?
|
| Inflammation | 3 | 2016 | 508 | 0.070 |
Why?
|
| Macaca mulatta | 2 | 2018 | 322 | 0.070 |
Why?
|
| Malvaceae | 1 | 2005 | 1 | 0.070 |
Why?
|
| Proanthocyanidins | 1 | 2005 | 1 | 0.070 |
Why?
|
| Biflavonoids | 1 | 2005 | 1 | 0.070 |
Why?
|
| Catechin | 1 | 2005 | 5 | 0.070 |
Why?
|
| Placentation | 1 | 2005 | 4 | 0.070 |
Why?
|
| Arteriovenous Malformations | 1 | 2005 | 7 | 0.070 |
Why?
|
| Embryonic Development | 1 | 2005 | 9 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2005 | 23 | 0.070 |
Why?
|
| Hematopoiesis | 1 | 2005 | 34 | 0.060 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2004 | 1 | 0.060 |
Why?
|
| Laminin | 1 | 2004 | 13 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2004 | 32 | 0.060 |
Why?
|
| Chemotaxis | 1 | 2004 | 23 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2004 | 29 | 0.060 |
Why?
|
| Actins | 1 | 2004 | 52 | 0.060 |
Why?
|
| Prognosis | 2 | 2019 | 1362 | 0.060 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2004 | 40 | 0.060 |
Why?
|
| Arthritis | 1 | 2005 | 37 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2004 | 86 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2005 | 60 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 73 | 0.060 |
Why?
|
| Diabetic Retinopathy | 1 | 2005 | 64 | 0.060 |
Why?
|
| Rats, Inbred F344 | 2 | 2014 | 125 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 248 | 0.060 |
Why?
|
| Middle Aged | 5 | 2019 | 10834 | 0.060 |
Why?
|
| Myosin Heavy Chains | 1 | 2004 | 86 | 0.060 |
Why?
|
| Salvage Therapy | 2 | 2016 | 118 | 0.060 |
Why?
|
| Cell Movement | 1 | 2004 | 161 | 0.060 |
Why?
|
| Wound Healing | 1 | 2005 | 182 | 0.060 |
Why?
|
| Collagen | 1 | 2004 | 217 | 0.060 |
Why?
|
| Apoptosis | 2 | 2002 | 337 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2018 | 143 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 711 | 0.050 |
Why?
|
| Dual Specificity Phosphatase 1 | 2 | 2013 | 29 | 0.050 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2001 | 1 | 0.050 |
Why?
|
| Pregnancy | 1 | 2005 | 815 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 249 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 97 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 90 | 0.050 |
Why?
|
| Aged | 4 | 2019 | 9492 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2010 | 158 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 32 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 36 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2000 | 63 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2000 | 38 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 71 | 0.050 |
Why?
|
| HMGA2 Protein | 1 | 2019 | 13 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 2019 | 26 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 2012 | 89 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2018 | 19 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 56 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 90 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 156 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 320 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 142 | 0.040 |
Why?
|
| Cell Division | 3 | 2002 | 97 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 98 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2013 | 799 | 0.040 |
Why?
|
| Stilbenes | 1 | 2016 | 25 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 118 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2016 | 103 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 81 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 301 | 0.030 |
Why?
|
| Adult | 3 | 2018 | 8426 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 980 | 0.030 |
Why?
|
| Rats, Inbred BN | 1 | 2014 | 32 | 0.030 |
Why?
|
| Dentate Gyrus | 1 | 2014 | 6 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 23 | 0.030 |
Why?
|
| Respiration | 1 | 2014 | 26 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2014 | 14 | 0.030 |
Why?
|
| Space Flight | 1 | 2014 | 19 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 76 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2014 | 24 | 0.030 |
Why?
|
| Ramipril | 1 | 2013 | 4 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 298 | 0.030 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2013 | 23 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2013 | 37 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 2021 | 0.030 |
Why?
|
| Tetrazoles | 1 | 2013 | 71 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2014 | 66 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 104 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 58 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 464 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 45 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2012 | 159 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2012 | 74 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2014 | 264 | 0.030 |
Why?
|
| Body Weight | 1 | 2014 | 290 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 152 | 0.030 |
Why?
|
| Motor Activity | 1 | 2014 | 310 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 546 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3112 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 436 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 450 | 0.020 |
Why?
|
| Neurons | 1 | 2014 | 394 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 3719 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 46 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 44 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 82 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 103 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 66 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 3101 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 2402 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2005 | 10 | 0.020 |
Why?
|
| Benzo(a)pyrene | 1 | 2005 | 4 | 0.020 |
Why?
|
| Serine | 1 | 2005 | 11 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2005 | 50 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2005 | 80 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2005 | 69 | 0.020 |
Why?
|
| Breast | 1 | 2005 | 53 | 0.020 |
Why?
|
| Antioxidants | 1 | 2005 | 114 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2005 | 138 | 0.020 |
Why?
|
| Mitochondria | 1 | 2005 | 174 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2001 | 4 | 0.010 |
Why?
|
| Thymidine | 1 | 2001 | 7 | 0.010 |
Why?
|
| G1 Phase | 1 | 2001 | 8 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 18 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2001 | 10 | 0.010 |
Why?
|
| Caspases | 1 | 2001 | 31 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2001 | 30 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 50 | 0.010 |
Why?
|
| Species Specificity | 1 | 2001 | 84 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2002 | 121 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 37 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 100 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2001 | 77 | 0.010 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2001 | 44 | 0.010 |
Why?
|
| Vasodilation | 1 | 2002 | 87 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 350 | 0.010 |
Why?
|
| Amidines | 1 | 2000 | 2 | 0.010 |
Why?
|
| Benzylamines | 1 | 2000 | 3 | 0.010 |
Why?
|
| Nitrobenzenes | 1 | 2000 | 10 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2000 | 12 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2000 | 15 | 0.010 |
Why?
|
| Asbestos | 1 | 2000 | 8 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2000 | 39 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2000 | 50 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2000 | 65 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 162 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2000 | 256 | 0.010 |
Why?
|
| Lung | 1 | 2000 | 233 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 641 | 0.010 |
Why?
|
Metheny-Barlow's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(234)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(33)
People in Profiles who have published with this person.
Explore
_
Similar People
(51)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_